This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This shift has led to the emergence of integrated contract development and manufacturing organizations (CDMOs), which provide end-to-end support for drugdevelopers. The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48 from 2023 to 2030.
This article outlines key considerations and strategies for developing a sustainable generic drugdevelopment strategy. Pfizer, for example, has been applying green chemistry principles in drugdevelopment for over two decades to reduce waste, minimize resource use, and develop energy-efficient manufacturing processes.
It follows that HER3-targeting therapies have emerged as a class of anti-cancer treatments designed to treat various tumors that have developed resistance to EGFR or HER2-directed therapies or have emerged due to a NRG1 gene fusion. This is an active drugdevelopment landscape with a lot of recent news.
Global Pharmaceutical Contract Sales Outsourcing Market to Reach $24.8 Billion by 2030: Strategic Insights, Regional Trends, and Technological Shifts Reshaping the Landscape The global pharmaceutical contract sales outsourcing (CSO) market is entering a transformative phase, with its value expected to grow from $17.3 In the U.S.,
trillion talent shortage projected by 2030. If your company is in the market for HR technology, a good place to start is to conduct employee journey mapping to understand employee needs, processes, and perceptions across key components of the employee lifecycle. Does the technology make it easier to complete the task?
Healthcare Trend #1: AI Disruption and Enablement Healthcare has seen a surge of interest in AI, with the market set to soar to $187.95 billion by 2030. Keep a pulse on what other healthcare organizations – especially new market entrants and disruptors – are doing. and data consistency and quality. Data as a Service, or DaaS).
Healthcare Trend #1: AI Disruption and Enablement Healthcare has seen a surge of interest in AI, with the market set to soar to $187.95 billion by 2030. Only then can data be richly woven into a reliable 360-degree view of the consumer that spans and supports better care management, marketing engagement, and support services.
The substantial value of organoids is becoming increasingly recognised by supportive government initiatives developing novel drugs, with a growth rate of 22 percent between 2023 and 2030 and a market size predicted to reach over US $6.5 billion by 2030. Front Genet. 2021;12(November):1–14. 2022 Dec 1;2(1):94.
The landscape of weight loss drugs has been rapidly evolving, and 2024 is poised to be another transformative year in this market. Pharmaceutical researchers, in particular, have a keen interest in understanding the unfolding dynamics of this market. Let’s delve into what lies ahead in the coming year.
These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. recent announcements from Merck and Sanofi for obesity and broader metabolic disease).
Each team supplies valuable insights throughout the design-make-test-analyse (DMTA) cycle to enable the effective design and optimisation of high-calibre drug candidates. Providing specialist and unique insight, CROs can propel a drug discovery process forward.
Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030. 1 With this growth comes increased demands for laboratory services at all steps across the development process.
Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drugdevelopment pipeline. The two broadest categories of drugdevelopment can be separated into the preclinical and clinical research stages. over this period.
Precedence Research reports that the global ophthalmic drugmarket size is estimated to double in 10 years, from $34.6 billion by 2030. The development of pharmacological interventions for many of these conditions has been accelerating, supported by new delivery methods and formulation approaches.
Today, millennials represent 32% of the automotive market shoppers, and by 2030, that number will increase to 50%. Because of this huge shift, millennials are not likely to respond to the same marketing strategies used to target their parents. I love it when some marketing agencies announce that they do paid advertising.
In fact, the global healthcare eCommerce market is projected to reach $994.2 billion by 2030. The ability to offer healthcare products and services digitally is more important than ever. But a complex regulatory landscape and data privacy and security concerns are formidable obstacles. What to Expect 11:30 A.M.
Did you know that the Global Healthcare Ecommerce Market is projected to reach a value of $994.2 Billion by 2030 1 ? In the meantime, check out this blog: Adobe Commerce: Leading the Way in Proactive Healthcare Experiences Vantage Market Research 1
trillion in potential contributions by 2030. Inventory and capacity optimization Generative AI can study demand and supply patterns to help generate inventory and capacity scenarios including peak operations, market fluctuations, and environmental, social and corporate governance (ESG) related disruptive patterns.
This change is one reason why it is so critical for OEMs to develop a closer relationship with consumers – not completely outsource the relationship to dealers as they have in the past. By 2030, over half of vehicle buyers will be millennials who have different expectations.
At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients. “We Re-imagining Radiology.
According to the 2022 Polaris Market Research Report , the global clinical trials outsourcing market reached USD 38.11 over the forecast period (2022-2030). Benefits of outsourcing to a CRO The drug discovery process is lengthy and expensive, with only a small percentage of drug candidates successfully making it to market.
To advance new therapies, pharmaceutical, biotech, and medical device companies engage contract research organizations (CROs) for their know-how in navigating the complex landscape of drugdevelopment and regulatory pathways and to run clinical trials. billion in 2030.
By 2030, the last of the 73 million baby boomers will cross the threshold into Medicare eligibility. In fact, in a recent market research project, we found that most of our respondents considered these technologies essential to keeping their independence as they age.
Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding. Specifically, the global ophthalmic clinical trials market, valued at USD 1.5 from 2023 to 2030. from 2023 to 2030.
According to a report by Grand View Research, the global CRO services market was valued at approximately US$50.55 from 2024 to 2030. billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 7.0%
The application of Artificial Intelligence (AI) in drug discovery is rapidly transforming the pharmaceutical industry, offering opportunities to accelerate the identification of novel therapeutic targets, optimize molecule design, and enhance clinical trial efficiency. billion in 2023 to $7.9
Investment Trends in Pharmaceutical Research and Development Investing in the pharmaceutical sector presents a unique set of challenges and opportunities; let’s examine them in more detail. The average cost of bringing a new drug to market is about $2.6 The market for cardiovascular drugs, valued at 155.6
With an administration that is pushing big goals for EV adoption by 2030, and consumer demand ramping up for the latest vehicle technology, OEMs and dealers are scrambling to ensure they stay on top of the game. Market Overall, the automotive industry is up 13%. Tighter than expected labor market. An Overview of the U.S.
Key Pipeline Progress Regeneron has more than 20 product candidates in clinical development, including five marketed products for which it is investigating additional indications. Assets: Cash and marketable securities. $. Non-GAAP net income per share – diluted (1). $. Business Highlights. In millions). 5,901.0. $.
trillion loss in GDP by 2030 shows the urgency of this crisis. The erosion of existing antibiotic efficacy due to resistance presents a challenge — an urgent public health crisis and a potential market opportunity. This costly, high-risk development pipeline has high attrition rates and uncertain market returns.
Recent research shows that the global B2B e-commerce market is expected to surge from $28.86 trillion by 2030, growing at an impressive annual rate of 15.95% (Mordor Intelligence). And dont forget your teamsales, support, and marketing must be aligned to provide consistent messaging and service across channels.
However, amid this progress, the complexities of drugdevelopment have never been more apparent. Food and Drug Administration (FDA) approved 38 new molecular entities for therapeutic use, a decline from 47 in the previous year. In 2024, the U.S. The data revealed five key trends poised to shape biopharma and biotech in 2025.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content